Evidence map›Paper›PMID 39686870›Full record

ArticleArchiv der Pharmazie2025

Exploring aliphatic sulfonamides as multiclass inhibitors of the carbonic anhydrases from the pathogen bacterium Vibrio cholerae.

Niccolò Paoletti, Simone Giovannuzzi, Alessandro Bonardi, Viviana De Luca, Clemente Capasso, Alessio Nocentini, Paola Gratteri, Claudiu T Supuran

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archiv der Pharmazie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Niccolò PaolettiNEUROFARBA Department, Laboratory of Molecular Modelling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.ORCID http://orcid.org/0000-0002-6874-9419
Simone GiovannuzziNEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Firenze, Italy.ORCID http://orcid.org/0000-0002-0669-7481
Alessandro BonardiNEUROFARBA Department, Laboratory of Molecular Modelling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.ORCID http://orcid.org/0000-0002-5520-740X
Viviana De LucaDepartment of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, Naples, Italy.
Clemente CapassoDepartment of Biology, Agriculture and Food Sciences, National Research Council (CNR), Institute of Biosciences and Bioresources, Naples, Italy.
Alessio NocentiniNEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Firenze, Italy.
Paola GratteriNEUROFARBA Department, Laboratory of Molecular Modelling, Cheminformatics & QSAR, University of Florence, Firenze, Italy.
Claudiu T SupuranNEUROFARBA Department, Pharmaceutical and Nutraceutical Section, University of Florence, Firenze, Italy.

Funding

European Union's Horizon 2020 research and innovation programme 951883
6 · The paper itself

Abstract

This study investigates aliphatic sulfonamide derivatives as inhibitors of the α-, β-, and γ-class carbonic anhydrase (CA) isoforms from Vibrio cholerae (VchCAs). A series of 26 compounds bearing a triazole linker and urea- or ether-based tails were described and evaluated for their inhibitory action using a stopped-flow CO

Indexed as

Carbonic Anhydrase InhibitorsCarbonic AnhydrasesSulfonamidesVibrio choleraeDose-Response Relationship, DrugHumansModels, MolecularMolecular StructureStructure-Activity RelationshipCarbonic Anhydrase InhibitorsCarbonic AnhydrasesSulfonamidesaliphatic sulfonamidesbacterial carbonic anhydraseenzyme inhibitionGram‐negativeVibrio cholerae

Identifiers

PMID39686870
PMCPMC11650360

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.